Healthcare Purchasing News
  • Magazine
  • Continuing Education
  • Webinars
  • Whitepapers
  • Videos
  • Events
  • Hall of Fame
  • Advertise
  • Source Guide
  • Subscribe
  • Sourcing & Logistics
  • Sterile Processing
  • Surgical & Critical Care
  • Patient Satisfaction
  • Infection Prevention
  • EVS & Facility Services
  • Healthcare IT
  • Regulatory
  • Topics
    Sourcing & LogisticsSterile ProcessingSurgical & Critical CarePatient SatisfactionInfection PreventionEVS & Facility ServicesHealthcare ITRegulatory
    Resources
    HPN Source GuideContinuing EducationWebinarsWhitepapersVideosEventsHall of FameAdvertiseAd Specs
    User Tools
    SubscribeContact UsAbout UseNewsletterMagazinesPrivacy PolicyTerms & Conditions
    https://www.facebook.com/hpnonline
    https://www.linkedin.com/company/healthcare-purchasing-news/
    https://twitter.com/HPN_Online
    1. Infection Prevention
    2. Screening & Surveillance

    Johns Hopkins Medicine researchers say SARS-CoV-2 booster doses should be investigated for immunocompromised patients

    June 15, 2021
    Image by Wilfried Pohnke from Pixabay
    Johns Hopkins Medicine Researchers Say Sars Co V 2 Booster Doses Should Be Investigated Immunocompromised Patients Pic 6 15 21du Syringe 5873159 1920 Pixabay

    Johns Hopkins Medicine researchers have shown that three doses of vaccine against SARS-CoV-2 increase antibody levels more than the standard two-dose regimen for people who have received solid organ transplants, according to a study published in the Annals of Internal Medicine, reported the school. The researchers say this finding suggests booster doses should be investigated for those who are immunocompromised.

    “Our findings suggest clinical trials are warranted to determine if transplant recipients should receive COVID-19 vaccine booster doses as standard clinical practice, similar to what is currently done with hepatitis B and influenza vaccinations for this population,” says study lead author William Werbel, M.D., an infectious diseases research fellow at the Johns Hopkins University School of Medicine.

    People who receive solid organ transplants (such as hearts, lungs and kidneys) often must take drugs to suppress their immune systems and prevent rejection. Such regimens may interfere with a transplant recipient’s ability to make antibodies to foreign substances, including the protective ones produced in response to vaccines.

    In the first of two previous studies, the researchers showed that only 17% of the participating transplant recipients produced sufficient antibodies after one dose. Then, in the second study, they found the level improved to 54% after the second shot. In both cases, even those transplant recipients with antibodies had levels well below what has been typically seen in people with healthy immune systems.

    In their latest study, the researchers evaluated 30 organ transplant recipients who received a third dose of one of three vaccines — Johnson & Johnson/Jansen, Moderna or Pfizer/BioNTech — between March 20 and May 10, 2021. They had previously received two doses of either the Moderna or Pfizer/BioNTech vaccine. The median age of the study participants was 57, 17 were women and one identified as non-white. No study participant reported an illness prior to vaccination or a positive test for SARS-CoV-2. All were taking multiple immunosuppressive medications to prevent rejection of their transplanted organs.

    “Our findings revealed that a third of the participants who had negative antibody levels and all who had low positive levels before the booster increased their immune response after a third vaccine dose,” says study senior author Dorry Segev, M.D., Ph.D., the Marjory K. and Thomas Pozefsky Professor of Surgery and Epidemiology and director of the Epidemiology Research Group in Organ Transplantation at the Johns Hopkins University School of Medicine.

    A week after receiving their third vaccine dose, 23 study participants completed a questionnaire about adverse effects. Reactions were generally mild or moderate, with one participant reporting severe arm pain and another a severe headache. No participant reported fever or an allergic reaction. There was one case of mild organ rejection during the study.

    “These reactions seem acceptable, considering the benefits that vaccines can confer,” says Segev.

    Werbel and Segev note that this study only examined antibody levels, and that future research is needed to see if the increased immune response after a third vaccine dose is associated with lower SARS-CoV-2 infection rates.

    “Although the third vaccine dose appears to raise the immune response of transplant recipients to higher levels than after one or two doses, these people may still be at greater risk for SARS-CoV-2 infection than the general population who have been vaccinated,” says Werbel. “Therefore, we recommend that transplant recipients and other immunocompromised people continue to wear masks, maintain physical distancing and practice other COVID-19 safety measures.”

    Johns Hopkins Medicine has the release.

    More COVID-19 coverage HERE.

    Latest in Screening & Surveillance

    By Gorodenkoff on AdobeStock
    Adobe Stock 416534355
    Screening & Surveillance

    Agreement hopes to spur enhanced, global access to COVID testing technologies

    June 16, 2022
    By ustas on AdobeStock
    Adobe Stock 229043399
    Screening & Surveillance

    New research shows severe COVID is in the genes

    June 15, 2022
    By Stockwerk-Fotodesign on Adobe Stock
    Adobe Stock 331271554
    Screening & Surveillance

    New study makes Delta the deadliest

    May 24, 2022
    Courtesy of the CDC
    Courtesy of the CDC
    Regulatory

    CDC update on children with Acute Hepatitis of Unknown Cause

    May 19, 2022
    Courtesy of UK Health Security Agency (UKHSA)
    Courtesy of UK Health Security Agency (UKHSA)
    Screening & Surveillance

    Four more cases of monkeypox identified by the UK Health Security Agency

    May 18, 2022
    Healthcare Purchasing News
    https://www.facebook.com/hpnonline
    https://www.linkedin.com/company/healthcare-purchasing-news/
    https://twitter.com/HPN_Online
    • About Us
    • Contact Us
    • Advertise
    • Do Not Sell or Share
    • Privacy Policy
    • Terms & Conditions
    © 2023 Endeavor Business Media, LLC. All rights reserved.
    Endeavor Business Media Logo